Contineum Therapeutics (CTNM) Gains from Investment Securities (2023 - 2024)

Contineum Therapeutics' (CTNM) quarterly Gains from Investment Securities came in at -$1000.0 in Q4 2024, up 66.67% year-on-year from -$600.0 in Q1 2024, and up 90.91% quarter-over-quarter from -$11000.0 in Q2 2024.

Contineum Therapeutics (CTNM) Gains from Investment Securities (2023 - 2024) Analysis & Trends

Contineum Therapeutics' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at -$1000.0 for Q4 2024.

  • On a quarterly basis, Gains from Investment Securities rose 66.67% year-over-year to -$1000.0 in Q4 2024; TTM through Sep 2025 was -$1000.0, a 100.97% decrease from a year earlier, with the FY2024 full-year figure at $106000.0, up 2220.0% from the prior year.
  • Gains from Investment Securities climbed to -$1000.0 in Q4 2024 per CTNM's latest filing, from -$11000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $117000.0 in Q1 2024 and bottomed at -$11000.0 in Q2 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Contineum Therapeutics 523.31 Mn 523.31 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2024 -1,000.00
Dec 31, 2024 -1,000.00
Jun 30, 2024 -11,000.00
Jun 30, 2024 -11,000.00
Mar 31, 2024 117,000.00
Mar 31, 2024 117,000.00
Dec 31, 2023 -3,000.00
Dec 31, 2023 -3,000.00
Jun 30, 2023 -2,000.00
Jun 30, 2023 -2,000.00